查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947969

口服补体抑制剂市场依药物类别、分子标靶和治疗应用划分，全球预测（2026-2032年）

Oral Complement Inhibitors Market by Drug Class, Molecular Target,, Therapeutic Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，口服补体抑制剂市场价值将达到 22 亿美元，到 2026 年将成长至 23 亿美元，到 2032 年将达到 33.8 亿美元，复合年增长率为 6.32%。

关键市场统计数据
基准年 2025 22亿美元
预计年份：2026年 23亿美元
预测年份 2032 33.8亿美元
复合年增长率 (%) 6.32%

口服补体抑制剂的策略性应用：聚焦临床原理、研发重点和相关人员，助力计画成功

补体标靶治疗领域正迅速发展，口服药物因其在临床医生、支付方和寻求肠外疗法替代方案的患者中日益增长的关注度而备受青睐。本执行摘要概述了口服补体抑制剂的临床原理、治疗标靶以及影响其研发和商业化路径的相关人员期望，从而为其提供策略背景。文中重点介绍了关键项目优先事项，包括对补体介导疾病的疗效、长期给药的安全性、患者使用便利性以及与现有治疗标准的兼容性。

药物设计、以病人为中心的照护模式以及监管机构对真实世界数据的接受程度的进步，正在如何重塑口服补体抑制剂的格局

过去几年，科学知识、药物设计和医疗服务领域的变革性变化共同重塑了补体抑制剂的竞争格局。分子药理学和转化免疫学的进步明确了标靶选择，使得设计口服生物利用度高、能更特异性调节补体活化的小分子成为可能。同时，药物化​​学的进步提高了口服暴露量、代谢稳定性和组织分布，这些进步共同降低了以往针对补体的小分子药物研发所面临的障碍。

评估近期美国关税调整和贸易政策转变如何推动专科药品供应链多元化和製造地结构重组。

2025年的贸易政策发展为生物製药和小分子治疗药物（包括口服补体抑制剂）的生产商和经销商带来了新的考量。进口关税表和执法通讯协定的调整增加了跨境供应链的行政负担，尤其是在从国际供应商采购活性药物成分（API）方面。因此，各公司正在重新评估其筹资策略，筛选合格的供应商，并实现製造地多元化，以降低单一来源风险并减少潜在的前置作业时间波动。

详细的細項分析将治疗适应症和作用机制的考虑因素与口服补剂方案中细緻的患者群体和临床策略联繫起来。

基于治疗用途的細項分析显示，临床重点主要集中在非典型溶血性尿毒症候群、遗传性血管性水肿和阵发性睡眠性血尿症。每种疾病都为药物研发和商业化带来了独特的挑战。非典型溶血性尿毒症候群的研发项目需要针对成人和儿童患者群体进行客製化，并充分考虑剂量考量、安全性监测需求和长期肾功能预后指标的差异。遗传性血管性水肿的研发项目分为急性治疗方案和预防方案。急性治疗方案要求起效迅速且疗效持久，而预防方案则优先考虑长期用药的耐受性和依从性。阵发性睡眠性血尿症的研发项目也同样分为成人和儿童两个部分，临床医生越来越多地评估口服维持治疗的可行性，无论是作为单药治疗还是与现有标准疗法联合治疗。

区域监管差异、支付方预期和临床基础设施如何塑造美洲、欧洲、中东和非洲以及亚太市场的差异化策略

区域趋势对口服补体抑制剂，美洲、欧洲、中东和非洲以及亚太地区之间存在显着差异。在美洲，监管机构和临床界对有严格疗效和安全性数据支持的创新口服疗法持开放态度，而支付方则越来越要求药物在改善患者体验和降低总医疗成本方面取得切实进展，以此作为药物获批上市的依据。因此，申办者通常会优先考虑全面的疗效数据和卫生经济模型，以推动市场进入的讨论。

来自策略联盟、敏捷生物技术公司和综合证据生成方法的日益激烈的竞争将推动专案差异化。

口服补体抑制剂领域的产业活动呈现多元化态势，既有成熟的製药公司，也有生技创新企业和专注于研发的专业公司，它们各自推进不同的产品线。主要企业正积极建立策略联盟，将补体生物学的基础专长与小分子化学、製剂科学和商业性执行的优势结合。这些合作通常包括共同开发契约、许可协议和共同促销框架，旨在加速临床项目并扩大地域覆盖范围。

整合临床设计、供应链韧性和支付方参与，加速口服补充疗法开发和推广的实用策略建议

产业领导者必须采取协作方式，整合科学、商业性和营运方面的努力，以加速口服补体抑制剂的研发和应用。首先，应优先进行临床项目，将生物标记指导的患者选择与对临床医生、监管机构和支付方有意义的终点指标相结合，以提高临床区分的清晰度和可靠性。其次，应儘早投资于製剂和药物动力学优化，以确保口服候选药物能够在不影响安全性的前提下实现标靶结合，并考虑与现有标准疗法互补的联合治疗策略。

我们采用综合性的多源调查方法，结合专家对话、监管和临床文献综合以及三角情境分析，来支持我们的策略结论。

本分析采用了多方面的调查方法，结合了专家访谈、对公开临床试验註册库和监管出版物的系统性回顾，以及对同行评审的转化医学和临床文献的综合分析。研究人员从血液学和免疫学临床医生、具有补体系统经验的药理学专家、供应链专家和支付方代表处收集了主要的定性数据，以使研究结果与实际情况相符。此外，研究人员还进行了二次研究，包括分析近期科学会议、监管指导文件以及已发表的安全性和有效性报告，确保了研究结果的技术基础。

将策略重点与科学检验、符合支付方利益的证据产生以及营运韧性相结合，以充分发挥口服补体疗法的潜力。

总之，口服补体抑制剂代表了补体介导疾病治疗管理的革命性转变，并有望提高治疗的便利性、依从性和门诊治疗模式。标靶检验和口服药物设计的科学进步，以及监管机构和支付方对以患者为中心的真实世界证据日益增长的认可，正推动对这些治疗方法的持续投资。然而，成功的临床转化需要密切关注患者分层、长期安全性监测以及与支付方价值框架的契合。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 口服补体抑制剂市场（依药物类别划分）

  • 阿巴科潘
  • 伊普塔科潘

9. 口服补体抑制剂市场－基于分子标靶的分类

  • D因子抑制剂
  • B 因子抑制剂
  • C5抑制剂

第十章：口服补体抑制剂市场

  • 血液疾病
  • 肾臟疾病
  • 神经系统疾病
  • 眼科疾病

11. 依治疗应用分類的口服补体抑制剂市场

  • 非典型溶血性尿毒症候群
    • 成年患者
    • 儿童患者
  • 遗传性血管性水肿
    • 急性治疗
    • 预防性治疗
  • 阵发性睡眠性血尿症
    • 成年患者
    • 儿童患者

12. 各地区口服补体抑制剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 口服补体抑制剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国口服补体抑制剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国补体抑制剂市场

第十六章：中国补体抑制剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Biocryst Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Omeros Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Swedish Orphan Biovitrum AB
  • UCB SA
Product Code: MRR-4F7A6D4FB6B3

The Oral Complement Inhibitors Market was valued at USD 2.20 billion in 2025 and is projected to grow to USD 2.30 billion in 2026, with a CAGR of 6.32%, reaching USD 3.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.20 billion
Estimated Year [2026] USD 2.30 billion
Forecast Year [2032] USD 3.38 billion
CAGR (%) 6.32%

A strategic introduction to oral complement inhibitors highlighting clinical rationale, development priorities, and stakeholder expectations shaping program success

The landscape of complement-targeted therapeutics is evolving rapidly as oral modalities attract heightened interest from clinicians, payers, and patients seeking alternatives to parenteral therapies. This executive summary introduces the strategic context for oral complement inhibitors by outlining the clinical rationale, therapeutic targets, and stakeholder expectations that shape development and commercialization pathways. It frames key programmatic priorities-efficacy in complement-mediated diseases, safety across chronic administration, ease of use for patients, and compatibility with existing standard-of-care treatments.

Given the heterogeneity of conditions driven by complement dysregulation, industry efforts increasingly emphasize precision in mechanism selection and patient stratification. Emerging oral agents aim to address unmet needs across rare, immune-mediated hematologic and vascular disorders by offering improved convenience and potential for at-home administration. As companies advance candidates through clinical development, regulatory pathways and real-world evidence generation play a central role in de-risking programs and demonstrating value to payers. Consequently, frontrunners must align clinical trial designs with meaningful clinical endpoints, robust safety monitoring plans, and pragmatic measures of patient-centric outcomes to accelerate adoption.

How advances in drug design, patient-centric care models, and regulatory acceptance of real-world evidence are reshaping the oral complement inhibitors landscape

Over the past several years, transformative shifts in scientific understanding, drug design, and healthcare delivery have converged to reshape the competitive environment for complement inhibitors. Advances in molecular pharmacology and translational immunology have clarified target selection, enabling the design of orally bioavailable small molecules that modulate complement activation with greater specificity. Parallel progress in medicinal chemistry has improved oral exposure, metabolic stability, and tissue distribution, which collectively lower the developmental barriers previously associated with complement-targeted small molecules.

Concurrently, the clinical paradigm is shifting from episodic, hospital-based interventions toward chronic, outpatient management. This shift is driven by a stronger emphasis on patient quality of life, the operational strain on infusion centers, and a desire to reduce caregiver burden. As a result, manufacturers are prioritizing formulations that support at-home dosing and treatment adherence. Moreover, regulatory authorities are increasingly receptive to patient-reported outcomes and real-world evidence as components of approval and labeling discussions, prompting sponsors to integrate pragmatic endpoints and decentralized trial elements early in program design. Thus, the combination of scientific feasibility and healthcare delivery momentum is accelerating the transition from injectable biologics to oral therapeutic options.

Assessing how recent US tariff adjustments and trade policy shifts are prompting supply chain diversification and manufacturing realignment for specialty therapeutics

Trade policy developments in 2025 have introduced new considerations for manufacturers and distributors of biologics and small-molecule therapies, including oral complement inhibitors. Adjustments to import duty schedules and enforcement protocols have increased the administrative burden for cross-border supply chains, particularly for active pharmaceutical ingredients sourced from international suppliers. As a result, companies are re-evaluating procurement strategies, qualifying additional suppliers, and diversifying manufacturing footprints to reduce exposure to single-source risks and to mitigate potential lead-time variability.

In response, commercial and supply chain teams are placing greater emphasis on nearshoring, regional manufacturing partnerships, and redundant inventory planning. These operational shifts aim to maintain continuity of supply while preserving pricing flexibility and payer agreements. At the same time, firms are strengthening regulatory and customs compliance functions to expedite clearance and reduce disruption. Given these dynamics, strategic planning must account for tariff-related friction in contracting and distribution negotiations, and stakeholders should prioritize scenario-based contingency planning to preserve patient access and prevent interruptions in therapy deployment.

Detailed segmentation insights link therapeutic indications and mechanism considerations to patient cohorts and clinical strategy nuances for oral complement programs

Segmentation analysis based on therapeutic application reveals a concentrated clinical focus on atypical hemolytic uremic syndrome, hereditary angioedema, and paroxysmal nocturnal hemoglobinuria, each presenting distinct development and commercialization imperatives. Within atypical hemolytic uremic syndrome, development programs must address both adult and pediatric patient populations, recognizing divergent dosing considerations, safety surveillance needs, and long-term renal outcome measures. Hereditary angioedema programs divide into acute treatment paradigms and prophylactic approaches, with acute therapies requiring rapid onset and predictable durability while prophylactic agents prioritize tolerability and adherence for chronic use. Paroxysmal nocturnal hemoglobinuria programs similarly segment into adult and pediatric cohorts, where clinicians increasingly assess the feasibility of oral maintenance therapy either as monotherapy or in combination with existing standards of care.

When considering mechanism of action, the current analytical framework includes C1 inhibitors as a primary category. Although historically administered parenterally, C1-targeted strategies are being re-examined in light of formulation science and mechanistic validation to determine whether oral delivery can achieve meaningful target engagement with acceptable safety margins. Across both therapeutic and mechanistic segments, patient selection, biomarker-driven endpoints, and age-specific safety profiles remain central to clinical strategy. Therefore, sponsors should align trial design with the nuances of each therapeutic subgroup to maximize clinical relevance and to support differentiated value propositions in payer and clinical discussions.

How regional regulatory variability, payer expectations, and clinical infrastructure shape differentiated strategies across Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a significant influence on development timelines, regulatory strategies, and commercial rollouts for oral complement inhibitors, with notable variation across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, regulatory agencies and clinical communities have shown a readiness to engage with innovative oral approaches when supported by rigorous efficacy and safety data, and payer systems increasingly look for demonstrable improvements in patient experience and total cost of care to justify formulary placement. Consequently, sponsors often prioritize comprehensive outcomes data and health economic models to facilitate market access discussions.

Within Europe Middle East & Africa, diverse regulatory frameworks and reimbursement pathways necessitate tailored country-level strategies. Stakeholders must navigate heterogeneous health technology assessment expectations, varying levels of rare disease infrastructure, and differing clinical practice patterns. Early alignment with regional opinion leaders and HTA bodies supports more efficient value demonstration. In the Asia-Pacific region, rapid clinical trial enrollment capacity, growing investment in local manufacturing, and evolving regulatory frameworks create opportunities for accelerated evidence generation and regional supply agreements. That said, successful commercialization in this region often requires culturally attuned patient engagement strategies and careful consideration of local reimbursement mechanisms.

Competitive dynamics driven by strategic alliances, nimble biotech innovators, and integrated evidence generation approaches shaping program differentiation

Industry activity around oral complement inhibitors reflects a mix of incumbent pharmaceutical companies, biotechnology innovators, and specialty developers advancing differentiated pipelines. Leading organizations are forming strategic alliances to combine foundational expertise in complement biology with strengths in small-molecule chemistry, formulation science, and commercial execution. These collaborations often include joint development agreements, licensing arrangements, and co-promotion frameworks designed to accelerate clinical programs and broaden geographic reach.

At the same time, nimble, clinical-stage companies are leveraging focused indications and biomarker-driven trial designs to create clear proof-of-concept inflection points that can attract partnerships or acquisition interest. Across the competitive landscape, successful programs demonstrate strong translational linkages between preclinical pharmacology and clinical endpoints, robust safety surveillance strategies for chronic administration, and data packages that address payer evidence needs. Strategic differentiation also emerges from integrated patient support services, digital adherence tools, and real-world data collection plans that enhance both clinician and payer confidence in long-term outcomes.

Actionable strategic recommendations for aligning clinical design, supply chain resilience, and payer engagement to accelerate development and adoption of oral complement therapies

Industry leaders should adopt a coordinated approach that aligns scientific, commercial, and operational initiatives to accelerate development and adoption of oral complement inhibitors. First, prioritize clinical programs that integrate biomarker-led patient selection and endpoint choices that matter to clinicians, regulators, and payers, thereby increasing the probability of clear, trustable clinical differentiation. Second, invest in formulation and pharmacokinetic optimization early to ensure oral candidates can achieve target engagement without compromising safety, and consider combination strategies that complement existing standards of care.

Operationally, companies should diversify supply chains and qualify multiple suppliers for critical intermediates and active ingredients to mitigate geopolitical and tariff-related risks. From a commercial perspective, developing robust health economic models and real-world evidence plans will facilitate reimbursement discussions and support value-based contracting where appropriate. Additionally, strengthen stakeholder engagement by involving patient advocacy groups, treating clinicians, and payers during development to ensure that trial designs and post-launch support align with real-world needs. Finally, consider modular launch plans that sequence indications and geographies based on clinical readiness, regulatory alignment, and payer receptivity to optimize resource allocation and market impact.

Comprehensive multi-source research methodology combining primary expert engagement, regulatory and clinical literature synthesis, and triangulated scenario analysis to support strategic conclusions

This analysis integrates a multi-source research methodology that combines primary expert interviews, systematic review of public clinical trial registries and regulatory publications, and synthesis of peer-reviewed translational and clinical literature. Primary qualitative inputs were obtained from clinicians specializing in hematology and immunology, pharmacology experts with complement experience, supply chain professionals, and payer representatives to ground findings in operational reality. Secondary research included analysis of recent scientific conferences, regulatory guidance documents, and published safety and efficacy reports to ensure the technical basis of insights.

Data triangulation was used to reconcile disparate sources and to surface consistent themes across clinical, commercial, and operational domains. Where evidence gaps existed, scenario-based analysis was employed to explore plausible outcomes and strategic responses. Limitations include the evolving nature of clinical pipelines and regulatory decisions, which may alter program trajectories; therefore, ongoing surveillance of late-stage trial readouts, approval actions, and real-world uptake metrics is recommended to refine strategic planning and to update risk assessments over time.

Synthesis of strategic priorities emphasizing scientific validation, payer-aligned evidence generation, and operational resilience to realize oral complement therapy potential

In conclusion, oral complement inhibitors represent a pivotal shift in the therapeutic management of complement-mediated disorders, offering the potential for improved convenience, adherence, and outpatient care models. Scientific progress in target validation and oral drug design, together with evolving regulatory and payer openness to patient-centered and real-world evidence, supports continued investment in these modalities. Nevertheless, successful translation to clinical use requires careful attention to patient stratification, chronic safety monitoring, and alignment with payer value frameworks.

Operational resilience is equally critical; supply chain diversification and regulatory foresight will mitigate tariff- and trade-related disruptions that can impact program timelines and patient access. Finally, collaborative approaches that combine the strengths of established industry players and agile innovators, anchored by rigorous evidence generation and stakeholder engagement, will be the most effective path to delivering durable clinical and commercial outcomes. Stakeholders who proactively integrate these considerations into development and launch planning will be best positioned to realize the promise of oral complement therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Complement Inhibitors Market, by Drug Class

  • 8.1. Avacopan
  • 8.2. Iptacopan

9. Oral Complement Inhibitors Market, by Molecular Target

  • 9.1. Factor D Inhibitors
  • 9.2. Factor B Inhibitors
  • 9.3. C5 Inhibitors

10. Oral Complement Inhibitors Market

  • 10.1. Hematological Disorders
  • 10.2. Renal Diseases
  • 10.3. Neurological Disorders
  • 10.4. Ophthalmological Diseases

11. Oral Complement Inhibitors Market, by Therapeutic Application

  • 11.1. Atypical Hemolytic Uremic Syndrome
    • 11.1.1. Adult Patients
    • 11.1.2. Pediatric Patients
  • 11.2. Hereditary Angioedema
    • 11.2.1. Acute Treatment
    • 11.2.2. Prophylactic Treatment
  • 11.3. Paroxysmal Nocturnal Hemoglobinuria
    • 11.3.1. Adult Patients
    • 11.3.2. Pediatric Patients

12. Oral Complement Inhibitors Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oral Complement Inhibitors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oral Complement Inhibitors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oral Complement Inhibitors Market

16. China Oral Complement Inhibitors Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Akari Therapeutics, Plc
  • 17.6. Alexion Pharmaceuticals, Inc.
  • 17.7. Amgen Inc.
  • 17.8. Apellis Pharmaceuticals, Inc.
  • 17.9. Biocryst Pharmaceuticals, Inc.
  • 17.10. ChemoCentryx, Inc.
  • 17.11. Ionis Pharmaceuticals, Inc.
  • 17.12. Johnson & Johnson Services, Inc.
  • 17.13. Merck & Co., Inc.
  • 17.14. Novartis AG
  • 17.15. Omeros Corporation
  • 17.16. Pfizer Inc.
  • 17.17. Regeneron Pharmaceuticals, Inc.
  • 17.18. Roche Holding AG
  • 17.19. Swedish Orphan Biovitrum AB
  • 17.20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY AVACOPAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY AVACOPAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY AVACOPAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY IPTACOPAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY IPTACOPAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY IPTACOPAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR D INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR D INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR D INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR B INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR B INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR B INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY RENAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY RENAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 141. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 165. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 173. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)